Colzyx After the EIC Accelerator: Wound Dressing Still Preclinical

Collagen VI is a structural protein found in almost every connective tissue of the body. Researchers have shown that parts of it also kill bacteria, a finding published in the Journal of Innate Immunity in 2012 and extended in the Journal of Immunology in 2018, in a paper with authors at Colzyx AB in Lund. Colzyx turned those peptide fragments into a wound dressing called WOUNDCOM, meant to close chronic wounds faster and to fight infection, including multi-drug resistant bacteria, at the same time.

In the EIC Accelerator pilot's October 2019 cut-off, the European Commission selected Colzyx for blended finance, a grant plus EIC equity. The grant was €2,514,575 for a €3,596,551.25 project that was to run a clinical trial in venous leg ulcers and win the CE mark, according to CORDIS. CORDIS records that the project was "terminated on 30 September 2024", 15 months before its planned end. The company's final report gives one reason: "unforeseen requirements from the German authority BfArM".

Where Colzyx Stands Now

Colzyx is still registered as an active limited company with Johnna Hafner as chief executive and Jens Hansson as chairman, according to Syna and hitta.se, which both draw on the Swedish company register. In 2019 the company was led by Eskil Söderlind, who was quoted as CEO and project coordinator in the EU's CORDIS results summary of the Phase 1 feasibility study. When the leadership changed is not public.

The company's website, dated 2026, describes Hafner as a medtech executive with more than 25 years in the US and Europe who previously worked at Johnson & Johnson, and presents Colzyx as "a regenerative biology company whose technology can power the next generation of biomaterials". Its investor page says Woundcom is "advancing toward U.S. market entry". Its most recent scientific output is a December 2025 paper in Biochimica et Biophysica Acta: Biomembranes on how the collagen VI peptides interact with bacterial membranes, written with the University of Strasbourg, with Mörgelin and a second author giving Colzyx as their affiliation.

The product has changed shape and target since the EU grant. CORDIS described a dressing for chronic wounds such as venous leg ulcers and diabetic foot ulcers. The website now describes Woundcom as "a Collagen I matrix incorporating proprietary human Collagen VI-derived peptides", and says the company will generate human evidence "beginning in plastic and reconstructive surgery". The technology is the same, so this article treats the company as active on its funded product, not as a pivot.

The Technology: Antibacterial Fragments of a Structural Protein

Collagen VI forms fine fibre networks around cells in skin, lungs and other tissues. The 2018 Journal of Immunology paper reported that the protein's von Willebrand factor type A-like domains carry cationic, amphipathic peptide sequences with broad activity against Gram-positive and Gram-negative bacteria, including in human skin infections. Such peptides work like many of the body's own host defence molecules, by disrupting bacterial membranes; the 2025 paper adds that cytotoxicity assays showed "minimal to no adverse effects" on human cells at concentrations that kill bacteria.

Most wound dressings either manage the wound environment, for example by holding moisture, or add an antiseptic such as silver. Colzyx's argument, set out in its 2018 Phase 1 project, is that a dressing carrying human-derived peptides can do both jobs: speed up closure and kill bacteria. Its website reports "~4× faster wound closure" in an infected pig wound model and ">99.99%" antimicrobial activity in laboratory tests, and states plainly that the "results have not yet been established in human clinical studies".

The intellectual property is real. Colzyx is the original assignee of US patents including US10793618B2, granted in October 2020, and US12134640B2, published in November 2024, both with a priority date of 21 January 2016. The company says it holds three patent families.

What WOUNDCOM Promised, and What CORDIS Shows

The grant agreement was signed on 24 April 2020 and the project started on 1 May 2020, with an end date of 31 December 2025, according to CORDIS and the EU funding record on North Data. Colzyx was the only beneficiary: the Commission's October 2019 list names no partner company for WOUNDCOM. The plan had four goals: manufacture clinical trial material to regulatory standards, test the dressing on chronic venous leg ulcers in a clinical trial, finish that validation study and obtain the CE mark, and build trust among partners and investors by proving efficacy and safety.

The final report is three sentences long on the work done. It says the project ran "as planned", that WOUNDCOM "was developed according to the regulatory requirements", and that the project "was prematurely ended due to unforeseen requirements from the German authority BfArM". BfArM is the German federal institute that authorises clinical investigations of medical devices. The report does not say what BfArM required, whether any patient was treated, or how much of the grant was spent. No study by Colzyx appears on ClinicalTrials.gov, and the FDA's 510(k) database returns no clearance for the company.

1. Clinical trial material made to regulatory standardsClaimedThe company's CORDIS report says so; no third party confirms it.
2. Clinical trial in chronic venous leg ulcersNot achievedProject terminated; the company's final report cites BfArM requirements. No trial registered or reported.
3. CE mark and commercial readinessNot achievedNo CE mark announced; the website still describes the product as preclinical.
4. Efficacy and safety validated for partners and investorsNot achievedNo human data published; no licence partner announced.

A grant pays for development, not for success, and a regulator's demands can stop a device trial for reasons outside a small company's control. But the outcome is clear: none of the clinical milestones the EIC grant was awarded for has been publicly reached, so this article rates the award as not delivered.

The Money

The blended finance award came with equity as well as the grant. The EIC Fund lists Colzyx in its portfolio of invested companies, describing it as a maker of "bioactive wound care products designed to combat multidrug-resistant bacteria". Neither the fund nor the company has published the amount or the date of the investment, and no private funding round has been announced.

The accounts show a company spending down its capital. Colzyx lost SEK 5.32 million in the year to April 2023, SEK 4.91 million in the year to April 2024 and SEK 2.91 million in the shorter period to December 2024, after it moved its year end, according to hitta.se; Syna gives the same SEK 2.91 million loss for the latest period. Equity fell from SEK 23.98 million to SEK 16.43 million, and total assets from SEK 30.83 million to SEK 17.22 million.

The sources disagree on revenue. Hitta.se lists turnover of SEK 8.13 million, SEK 8.22 million and SEK 2.45 million for the three periods, while Syna reports net sales of SEK 287,000 for the latest period. The filed accounts themselves were not reviewed for this article, so what the larger figures contain could not be verified. Salaries to staff other than the board and CEO fell from SEK 2.35 million to SEK 2.19 million between the two full years. Neither register showed accounts for 2025 when checked for this article.

Why Europe Should Care

Antimicrobial resistance is one of the EU's stated health priorities. More than 35,000 people die each year in the EU and EEA from infections with resistant bacteria, according to the European Centre for Disease Prevention and Control. The Commission's One Health Action Plan of June 2017 and a Council Recommendation of 13 June 2023 call for more research and innovation against resistant infections. A wound dressing that kills bacteria without antibiotics fits that agenda.

The case also shows the friction between EU innovation funding and EU device regulation. The EIC selected the project for its promise; a national authority applying the device rules then set requirements that, by the company's account, ended it. The company's new focus on US market entry means that if Woundcom reaches patients, it may do so outside Europe first.

The Verdict

Colzyx has not been asked for comment for this article. It is based entirely on public records, company statements and EU project data, linked throughout.